HeartFlow vs. Iovance Biotherapeutics: Best Healthcare Buy for 2026
Two healthcare stocks are competing for investor attention heading into 2026. Here's how HeartFlow and Iovance Biotherapeutics stack up.
Two emerging healthcare companies — HeartFlow and Iovance Biotherapeutics — are drawing investor scrutiny as portfolio managers position for 2026, with analysts weighing each firm's commercial trajectory, competitive moat, and near-term catalysts against mounting sector uncertainty.
HeartFlow has carved out a niche in AI-driven cardiac diagnostics, offering a non-invasive coronary artery disease assessment tool that has gained traction among hospitals seeking to reduce costly and risky invasive procedures. Its technology platform targets a large and underserved patient population, giving the company a potentially durable growth runway if reimbursement pathways continue to expand.
Read more Kraken Adds Tokenized Stocks as Collateral for Leveraged Trading →
Iovance Biotherapeutics, by contrast, operates in the high-stakes oncology space, developing tumor-infiltrating lymphocyte therapies designed to treat advanced cancers. The company has been working to establish commercial footing for its lead therapy, a process that requires navigating complex manufacturing scale-up challenges and building out a specialized sales infrastructure — hurdles that are common but consequential for cell-therapy biotechs.
The comparison between these two names reflects a broader tension in healthcare investing: the relative safety of a medtech company with an approved, revenue-generating platform versus the higher-risk, higher-reward profile of a clinical-stage or early-commercial biotech. Investors weighing the two must consider their own tolerance for volatility, time horizon, and conviction in each company's ability to execute operationally over the next 12 to 24 months.
For a full breakdown of which stock Motley Fool analysts favor heading into 2026 — including valuation metrics and key risks — continue reading at fool.
